Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

计划入组 7 人 · 首次发布于 2019 年 8 月 6 日

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

计划入组 8 人 · 首次发布于 2018 年 4 月 18 日

A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers

计划入组 8 人 · 首次发布于 2020 年 3 月 26 日

OP-3136

OP-01

OP-145

Universitetet i Oslo

Norway

I-SHOU UNIVERSITY

Taiwan

i-SENS, Inc.

South Korea

Skin-Permeable Polymer Delivers Insulin Through Topical Cream, Offering Needle-Free Diabetes Treatment

Olema Oncology's KAT6 Inhibitor OP-3136 Receives FDA IND Clearance, Phase 1 Trial Planned for 2025

Olema's KAT6 Inhibitor OP-3136 Shows Promising Anti-Tumor Activity Across Multiple Cancer Types